The DOI matches its Crossref record; 37 of the 40 references it cites were found in a registry or an index, and 3 are not checked yet.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Open accessAbstract
BACKGROUND: The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. METHODS: We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. RESULTS: At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the intensive-treatment group and 136.2 mm Hg in the standard-treatment group. The intervention was stopped early after a median follow-up of 3.26 years owing to a significantly lower rate of the primary composite outcome in the intensive-treatment group than in the standard-treatment group (1.65% per year vs. 2.19% per year; hazard ratio with intensive treatment, 0.75; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). All-cause mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90; P=0.003). Rates of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not of injurious falls, were higher in the intensive-treatment group than in the standard-treatment group. CONCLUSIONS: Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01206062.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Systolic Blood Pressure Intervention Trial, 261 patients at high cardiovascular risk who were already using antihypertensive drugs targeting a systolic BP of 120 mmHg had an approximately twofold risk of syncope vs. the control group targeting a systolic BP of 140 mmHg.”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [261]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results have been interpreted to be generally consistent between the two trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (38,40).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular benefit of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The primary composite outcome of MI, coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (38).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The results of BPROAD and ESPRIT are supported by the Systolic Blood Pressure Intervention Trial (SPRINT), which demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (44).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
In the citing paper
“in which there was a notable 25% relative/0.5% absolute reduced risk per year of cardiovascular morbidity and mortality with intensive (<120 mm Hg) as compared with standard (<140 mm Hg) systolic blood pressure control in patients with hypertension and high cardiovascular risk.71”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [71]
In the citing paper
“This graded approach is based on evidence from multiple meta-analyses and individual RCTs, which show a consistent and graded reduction in CVD risk in response to reductions in TC and LDL-C levels. 61-71”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“These trials are consistent in showing that the higher the initial LDL-C level, the greater the absolute reduction in risk, while the relative risk reduction remains constant at any given baseline LDL-C level.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“The primary composite outcome of myocardial infarction (MI), coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a target systolic blood pressure of < 120 mmHg decreases cardiovascular event rates by 25% in high-risk patients, although people with diabetes were excluded from this trial (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Of note, the ACCORD BP and SPRINT trials targeted a similar systolic blood pressure < 120 mmHg, but in contrast to SPRINT, the primary composite cardiovascular end point was nonsigni fi cantly reduced in ACCORD BP.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The achieved systolic blood pressures in the trial were 121 mmHg and 136 mmHg in the intensive versus standard treatment group, respectively.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular bene fi t of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The results have been interpreted to be generally consistent between both trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Global burden of hypertension: analysis of worldwide data
Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17741-1 · Cited by 8,698
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Self-citationHeart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Research works printed but not linked: 3
- 10.1016/s0140-6736(05)70151-3 · DOI
- Franklin SS, 1999, Pathol Biol (Paris), 47, 594
- Nwankwo T, 2013, NCHS Data Brief, 133, 1
Cited by
Sorted by citations
Items 201–300 of 1,036
Bhakta, N. R., Bime, C., Kaminsky, D. A., McCormack, M. C., Thakur, N., Stanojevic, S., Baugh, A. D., Braun, L., Lovinsky‐Desir, S., Adamson, R., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202302-0310st · Cited by 316
Böhm, M., Schumacher, H., Teo, K. K., Lonn, E. M., Mahfoud, F., Mann, J. F. E., Mancia, G., Redon, J., Schmieder, R. E., Sliwa, K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30754-7 · Cited by 315
Mahfoud, F., Böhm, M., Schmieder, R. E., Narkiewicz, K., Ewen, S., Ruilope, L. M., Schlaich, M. P., Williams, B., Fahy, M. P., & Mancia, G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz118 · Cited by 310
Relation between blood pressure and pulse wave velocity for human arteries
Ma, Y., Choi, J., Hourlier-Fargette, A., Xue, Y., Chung, H. U., Lee, J. Y., Wang, X., Xie, Z., Kang, D., Wang, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814392115 · Cited by 309
Schiavon, C. A., Bersch-Ferreira, A. C., Santucci, E. V., Oliveira, J. D., Torreglosa, C. R., Bueno, P. T., Frayha, J. C., Santos, R. N., Damiani, L. P., Noujaim, P. M., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032130 · Cited by 308
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action
Bello, A. K., Alrukhaimi, M. N., Ashuntantang, G., Basnet, S., Correa‐Rotter, R., Douthat, W., Kazancıoğlu, R., Köttgen, A., Nangaku, M., Powe, N. R., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.007 · Cited by 304
Borger, M. A., Fedak, P. W. M., Stephens, E. H., Gleason, T. G., Girdauskas, E., Ikonomidis, J. S., Khoynezhad, A. B., Siu, S. C., Verma, S., Hope, M. D., et al. (2018) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.02.115 · Cited by 300
Thomopoulos, C., Parati, G., & Zanchetti, A. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000881 · Cited by 298
Nocturnal Hypertension: New Technology and Evidence
Kario, K. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.10971 · Cited by 298
DORANS, K. S., Mills, K. T., Liu, Y., & He, J. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008888 · Cited by 297
Brouwers, S., Sudano, I., Kokubo, Y., & Sulaica, E. M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00221-x · Cited by 297
Aggarwal, R., Yeh, R. W., Maddox, K. E. J., & Wadhera, R. K. (2023) · JAMA · doi:10.1001/jama.2023.2307 · Cited by 295
Gornik, H. L., Aronow, H. D., Goodney, P. P., Arya, S., Brewster, L. P., Byrd, L., Chandra, V., Drachman, D. E., Eaves, J. M., Ehrman, J. K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.013 · Cited by 294
Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes
Berlowitz, D. R., Foy, C. G., Kazis, L. E., Bolin, L. P., Conroy, M. B., Fitzpatrick, P. M., Gure, T. R., Kimmel, P. L., Kirchner, K. A., Morisky, D. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611179 · Cited by 290
Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control
Bress, A. P., Bellows, B. K., King, J. B., Hess, R., Beddhu, S., Zhang, Z., Berlowitz, D. R., Conroy, M. B., Fine, L. J., Oparil, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmsa1616035 · Cited by 289
Longitudinal Trends in Hypertension Management and Mortality Among Octogenarians
Dregan, A., Ravindrarajah, R., Hazra, N. C., Hamada, S., Jackson, S. H., & Gulliford, M. C. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07246 · Cited by 286
Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism
Arlt, W., Lang, K., Sitch, A. J., Dietz, A. S., Rhayem, Y., Bancos, I., Feuchtinger, A., Chortis, V., Gilligan, L. C., Ludwig, P., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93136 · Cited by 281
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease
Jung, C., & Yoo, T. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0329 · Cited by 283
Accuracy of Cuff-Measured Blood Pressure
Picone, D. S., Schultz, M. G., Otahal, P., Aakhus, S., Al-Jumaily, A. M., Black, J. A., Bos, W. J., Chambers, J. B., Chen, C.-H., Cheng, H.-M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.05.064 · Cited by 277
Aging Hallmarks and Progression and Age-Related Diseases: A Landscape View of Research Advancement
Tenchov, R., Sasso, J. M., Wang, X., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00531 · Cited by 276
Activation of Human T Cells in Hypertension
Itani, H. A., McMaster, W. G., Saleh, M. A., Nazarewicz, R. R., Mikolajczyk, T. P., Kaszuba, A., Konior, A., Prejbisz, A., Januszewicz, A., Norlander, A. E., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07237 · Cited by 273
Lee, H., Shin, J., Kim, G., Park, S., Ihm, S., Kim, H. C., Kim, K., Kim, J. H., Lee, J. H., Park, J., et al. (2019) · Clinical Hypertension · doi:10.1186/s40885-019-0124-x · Cited by 274
Hypertension and Heart Failure
Slivnick, J. A., & Lampert, B. C. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.06.007 · Cited by 275
Hypertension in Chronic Kidney Disease
Hamrahian, S. M., & Falkner, B. E. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_84 · Cited by 271
2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4103 · Cited by 271
Disorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 270
2024 Clinical practice guidelines for Hypertension in adults
Кобалава, Ж. Д., Конради, А. О., Nedogoda, S. V., Shlyakhto, E. V., Arutyunov, G. P., Баранова, Е. И., Барбараш, О. Л., Bobkova, N. V., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6117 · Cited by 274
Hypertension and incident cardiovascular events following ibrutinib initiation
Dickerson, T., Wiczer, T. E., Waller, A., Philippon, J., Porter, K. M., Haddad, D. A., Guha, A., Rogers, K. A., Bhat, S. A., Byrd, J. C., et al. (2019) · Blood · doi:10.1182/blood.2019000840 · Cited by 264
Hypertensive Disorders of Pregnancy and Future Maternal Cardiovascular Risk
Ying, W., Catov, J. M., & Ouyang, P. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009382 · Cited by 262
Hypertension and Atrial Fibrillation
Verdecchia, P., Angeli, F., & Reboldi, G. (2018) · Circulation Research · doi:10.1161/circresaha.117.311402 · Cited by 259
Liu, J., Li, Y., Ge, J., Yan, X., Zhang, H., Zheng, X., Lu, J., Li, X., Gao, Y., Lei, L., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01028-6 · Cited by 258
Precision medicine in cardiology
Antman, E. M., & Loscalzo, J. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.101 · Cited by 258
Swanepoel, C. R., Atta, M. G., D’Agati, V. D., Estrella, M. M., Fogo, A. B., Naicker, S., Post, F. A., Wearne, N., Winkler, C. A., Cheung, M., et al. (2018) · Kidney International · doi:10.1016/j.kint.2017.11.007 · Cited by 254
Association of Estimated Pulse Wave Velocity With Survival
Vlachopoulos, C. V., Terentes-Printzios, D. G., Laurent, S., Nilsson, P. M., Protogerou, A. D., Aznaouridis, K., Xaplanteris, P., Koutagiar, I. P., Tomiyama, H., Yamashina, A., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.12831 · Cited by 253
2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 251
Prevention of stroke: a strategic global imperative
Feigin, V. L., Norrving, B., George, M. G., Foltz, J. L., Roth, G. A., & Mensah, G. A. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.107 · Cited by 250
Update on the pathophysiology and medical treatment of peripheral artery disease
Golledge, J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00663-9 · Cited by 249
Lui, G. K., Saidi, A. S., Bhatt, A. B., Burchill, L. J., Deen, J. F., Earing, M. G., Gewitz, M. H., Ginns, J. N., Kay, J. D., Kim, Y. Y., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000535 · Cited by 244
Sarafidis, P. A., Persu, A., Agarwal, R., Burnier, M., de Leeuw, P. W., Ferro, C. J., Halimi, J., Heine, G. H., Jadoul, M. Y., Jarraya, F., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw433 · Cited by 242
Gerdts (2022) · doi:10.1093/eurheartj/ehac470 · Cited by 241
Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial)
Johnson, K., Whelton, P. K., Cushman, W. C., Cutler, J. A., Evans, G. W., Snyder, J. K., Ambrosius, W. T., Beddhu, S., Cheung, A. K., Fine, L. J., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10479 · Cited by 240
Heart failure with reduced ejection fraction
Bloom, M. W., Greenberg, B., Jaarsma, T., Januzzi, J. L., Lam, C. S. P., Maggioni, A. P., Trochu, J., & Butler, J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.58 · Cited by 239
ACC/AHA Versus ESC Guidelines on Heart Failure
van der Meer, P., Gaggin, H. K., & DEC, G. W. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.478 · Cited by 238
Circadian mechanisms of 24-hour blood pressure regulation and patterning
Smolensky, M. H., Hermida, R. C., & Portaluppi, F. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.02.003 · Cited by 237
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 275
Heart failure with preserved ejection fraction
Gladden, J. D., Linke, W. A., & Redfield, M. M. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1480-8 · Cited by 235
Hanssen, H., Boardman, H., Deiseroth, A., Moholdt, T. T., Simonenko, M., Kränkel, N., Niebauer, J., Tiberi, M., Abreu, A., Solberg, E. E., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa141 · Cited by 233
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Hur, K. Y., Moon, M. K., Park, J. S., Kim, S., Lee, S., Yun, J., Baek, J. H., Noh, J., Lee, B., Oh, T. J., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0156 · Cited by 233
Sex Differences in Hypertension: Where We Have Been and Where We Are Going
Ramirez, L. A., & Sullivan, J. C. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy148 · Cited by 231
The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma
Zaman, S. J., Wasfy, J. H., Kapil, V., Ziaeian, B., Parsonage, W. A., Sriswasdi, S., Chico, T., Capodanno, D., Colleran, R., Sutton, N. R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00055-8 · Cited by 236
Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke
Kitagawa, K., Yamamoto, Y., Arima, H., Maeda, T., Sunami, N., Kanzawa, T., 江口, 和., Kamiyama, K., Minematsu, K., Ueda, S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2167 · Cited by 230
Hypertension management in patients with cardiovascular comorbidities
Lauder, L., Mahfoud, F., Azizi, M., Bhatt, D. L., Ewen, S., Kario, K., Parati, G., Rossignol, P., Schlaich, M. P., Teo, K. K., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac395 · Cited by 232
Williams, B., Cockcroft, J. R., Kario, K., Zappe, D., Brunel, P., Wang, Q., & Guo, W. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08556 · Cited by 226
Treatment of Resistant and Refractory Hypertension
Acelajado, M. C., Hughes, Z. H., Oparil, S., & Calhoun, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.118.312156 · Cited by 226
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
Bi, Y., Li, M., Liu, Y., Li, T., Lu, J., Duan, P., Xu, F., Dong, Q., Wang, A., Wang, T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2412006 · Cited by 224
Guideline-Driven Management of Hypertension
Carey, R. M., Wright, J. T., Taler, S. J., & Whelton, P. K. (2021) · Circulation Research · doi:10.1161/circresaha.121.318083 · Cited by 224
9. Cardiovascular Disease and Risk Management
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s012 · Cited by 223
Reboussin, D. M., Allen, N. B., Griswold, M. E., Guallar, E., Hong, Y., Lackland, D. T., Miller, E. (. R., Polonsky, T., Thompson-Paul, A. M., & Vupputuri, S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.004 · Cited by 221
Touyz, R. M., Herrmann, S. M., & Herrmann, J. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.03.008 · Cited by 221
Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis
Semb, A. G., Ikdahl, E., Wibetoe, G., Crowson, C. S., & Rollefstad, S. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0428-y · Cited by 221
Malhotra, R., Nguyen, H. A., Benavente, O., Mete, M., Howard, B. V., Mant, J., Odden, M. C., Peralta, C. A., Cheung, A. K., Nadkarni, G. N., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.4377 · Cited by 220
Al‐Jawaldeh, A., & Abbass, M. M. S. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.817808 · Cited by 225
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
Kim, M. K., Ko, S., Kim, B., Kang, E. S., Noh, J., Kim, S., Park, S.-O., Hur, K. Y., Chon, S., Moon, M. K., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0137 · Cited by 218
Some methods for heterogeneous treatment effect estimation in high dimensions
Powers, S., Qian, J., Jung, K., Schuler, A., Shah, N. H., Hastie, T. J., & Tibshirani, R. J. (2018) · Statistics in Medicine · doi:10.1002/sim.7623 · Cited by 211
Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial
Kjeldsen, S. E., Lund‐Johansen, P., Nilsson, P. M., & Mancia, G. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07257 · Cited by 210
Sex Differences in Myocardial and Vascular Aging
Ji, H., Kwan, A. C., Chen, M. T., Ouyang, D., Ebinger, J. E., Bell, S. P., Niiranen, T., Bello, N. A., & Cheng, S. C. (2022) · Circulation Research · doi:10.1161/circresaha.121.319902 · Cited by 210
New Insights Into Cerebrovascular Pathophysiology and Hypertension
Webb, A. J. S., & Werring, D. J. (2022) · Stroke · doi:10.1161/strokeaha.121.035850 · Cited by 210
The global burden of hypertension exceeds 1.4 billion people
Egan, B. M., Kjeldsen, S. E., Grassi, G. M., Esler, M., & Mancia, G. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002021 · Cited by 207
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy
Touyz, R. M., & Herrmann, J. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0056-z · Cited by 204
Lv, Y., Gao, X., Yin, Z., Chen, H.-S., Luo, J., Brasher, M. S., Kraus, V. B., Li, T.-T., Zeng, Y., & Shi, X. (2018) · BMJ · doi:10.1136/bmj.k2158 · Cited by 203
10-Year Risk Equations for Incident Heart Failure in the General Population
Khan, S. S., Ning, H., Shah, S. J., Yancy, C. W., Carnethon, M. R., Berry, J. D., Mentz, R. J., O'Brien, E. C., Correa, A., Suthahar, N., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.057 · Cited by 203
Blanco, P. J., Müller, L. O., & Spence, J. D. (2017) · Stroke and Vascular Neurology · doi:10.1136/svn-2017-000087 · Cited by 202
Blood Pressure Assessment in Adults in Clinical Practice and Clinic-Based Research
Muntner, P., Einhorn, P. T., Cushman, W. C., Whelton, P. K., Bello, N. A., Drawz, P. E., Green, B. B., Jones, D. W., Juraschek, S. P., Margolis, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.069 · Cited by 199
Bonner, R., Albajrami, O., Hudspeth, J. C., & Upadhyay, A. (2020) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2020.08.004 · Cited by 200
Mental stress and human cardiovascular disease
Esler, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.011 · Cited by 197
Khera, R., Lu, Y., Lu, J., Saxena, A., Nasir, K., Jiang, L., & Krumholz, H. M. (2018) · BMJ · doi:10.1136/bmj.k2357 · Cited by 196
Hypertension and Heart Failure
Palo, K. E. D., & Barone, N. J. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.09.001 · Cited by 196
Sheppard, J. P., Burt, J., Lown, M., Temple, E., Lowe, R., Fraser, R., Allen, J., Ford, G. A., Heneghan, C., Hobbs, F. D. R., et al. (2020) · JAMA · doi:10.1001/jama.2020.4871 · Cited by 192
Machine learning in precision diabetes care and cardiovascular risk prediction
Oikonomou, E. K., & Khera, R. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01985-3 · Cited by 190
Chen, R., Suchard, M. A., Krumholz, H. M., Schuemie, M. J., Shea, S., Duke, J., Pratt, N., Reich, C. G., Madigan, D., You, S. C., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16667 · Cited by 190
Midlife Hypertension and Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Lennon, M. J., Makkar, S. R., Crawford, J. D., & Sachdev, P. S. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190474 · Cited by 190
Barbato, E., Azizi, M., Schmieder, R. E., Lauder, L., Böhm, M., Brouwers, S., Bruno, R. M., Dudek, D., Kahan, T., Kandzari, D. E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad054 · Cited by 188
Blood Pressure Reduction and Secondary Stroke Prevention
Katsanos, A. H., Filippatou, A. G., Manios, E. D., Deftereos, S. G., Parissis, J., Frogoudaki, A., Vrettou, A., Ikonomidis, I., Pikilidou, M. I., Kargiotis, O., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.08485 · Cited by 187
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
Inker, L. A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G. B., Badve, S. V., Caravaca‐Fontán, F., Vecchio, L. D., Floege, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02418-0 · Cited by 189
Ding, X., Zhao, N., Yang, G., Pettigrew, R. I., Lo, B. P. L., Miao, F., Li, Y., Liu, J., & Zhang, Y. (2016) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2016.2620995 · Cited by 184
Bangalore, S., Toklu, B., Gianos, E., Schwartzbard, A. Z., WEINTRAUB, H. S., Ogedegbe, G. G., & Messerli, F. H. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.01.004 · Cited by 184
Evaluating the relaxation effects of emerging forest-therapy tourism: A multidisciplinary approach
Ohe, Y., Ikei, H., Song, C., & Miyazaki, Y. (2017) · Tourism Management · doi:10.1016/j.tourman.2017.04.010 · Cited by 184
Prevalence and control rates of hypertension in the USA: 2017–2018
Chobufo, M. D., Gayam, V. B. R., Soluny, J., Rahman, E. U., Enoru, S. T., Foryoung, J. B., Agbor, V. N., Dufresne, A., & Nfor, T. (2020) · International Journal of Cardiology Hypertension · doi:10.1016/j.ijchy.2020.100044 · Cited by 183
Mendelian randomisation in cardiovascular research: an introduction for clinicians
Bennett, D., & Holmes, M. V. (2017) · Heart · doi:10.1136/heartjnl-2016-310605 · Cited by 181
Bénétos, A., Bulpitt, C. J., Petrović, M., Ungar, A., Rosei, E. A., Cherubini, A., Redón, J., Grodzicki, T. K., Dominiczak, A. F., Strandberg, T. E., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.07020 · Cited by 180
Lacey, B., Lewington, S., Clarke, R., Kong, X. L., Chen, Y., Yu, C., Yang, L., Bennett, D., Bragg, F., Bian, Z., et al. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30217-1 · Cited by 180
ESO Guideline on covert cerebral small vessel disease
Wardlaw, J. M., Debette, S., Jokinen, H., de Leeuw, F., Pantoni, L., Chabriat, H., Staals, J., Doubal, F., Rudilosso, S., Eppinger, S., et al. (2021) · European Stroke Journal · doi:10.1177/23969873211012132 · Cited by 178
RetractedChallenges in secondary prevention after acute myocardial infarction: A call for action
Piepoli, M. F., Corrà, U., Dendale, P., Frederix, I., Prescott, E., Schmid, J. P., Cupples, M., Deaton, C., Doherty, P., Giannuzzi, P., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316663873 · Cited by 177
The Frailty Syndrome and Outcomes in the TOPCAT Trial
Sanders, N. A., Supiano, M. A., Lewis, E. F., Liu, J., Claggett, B. L., Pfeffer, M. A., Desai, A. S., Sweitzer, N. K., Solomon, S. D., & Fang, J. C. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1308 · Cited by 176
Reboussin, D. M., Allen, N. B., Griswold, M. E., Guallar, E., Hong, Y., Lackland, D. T., Miller, E. (. R., Polonsky, T., Thompson-Paul, A. M., & Vupputuri, S. (2018) · Hypertension · doi:10.1161/hyp.0000000000000067 · Cited by 175
Itani, H. A., Xiao, L., Saleh, M. A., Wu, J., Pilkinton, M. A., Dale, B. L., Barbaro, N. R., Foss, J. D., Kirabo, A., Montaniel, K. R. C., et al. (2016) · Circulation Research · doi:10.1161/circresaha.115.308111 · Cited by 174
Chow, C. K., Atkins, E., Hillis, G. S., Nelson, M. R., Reid, C. M., Schlaich, M. P., Hay, P. D., Rogers, K. D., Billot, L., Burke, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01922-x · Cited by 174
Metadata
- Authors
- The SPRINT Research Group
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Corresponding author
- The SPRINT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2103-2116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4689591
- OpenAlex
- W3150595609
- Cited by
- 6,325
- References
- 38
- Citations by year
- 2026: 390 · 2025: 449 · 2024: 437 · 2023: 498 · 2022: 523 · 2021: 602 · 2020: 570 · 2019: 694 · 2018: 734 · 2017: 767 · 2016: 613 · 2015: 40
- FWCI
- 522.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000093, UL1TR000050, UL1TR001427, UL1TR000073, UL1TR001064, UL1TR001085, UL1TR000002, UL1TR000075, UL1TR000064, UL1TR000005, UL1TR000433, UL1TR000003, UL1TR000445, UL1TR000439, UL1TR000105)
- National Institute on Aging (P30AG021332)
- National Heart, Lung, and Blood Institute (HHSN268200900040C, A-HL-13-002-001, HHSN268200900049C, HHSN268200900048C, HHSN268200900047C, HHSN268200900046C)
- National Institute of General Medical Sciences (P30GM103337)
- National Center for Research Resources (UL1RR025755, UL1RR024134, UL1RR025752, UL1RR025771)
- National Center for Advancing Translational Sciences (9U54TR000017‐06)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- intensive blood pressure control, systolic blood pressure target, antihypertensive therapy, cardiovascular risk, cardiovascular events, all-cause mortality, adverse events, hypotension, acute kidney injury, non-diabetic patients
- MeSH terms
- Age Factors, Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Cause of Death, Female, Goals, Humans, Hypertension, Male, Middle Aged, Risk Factors, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
